Phase II study of the 2nd line Nab-PTX/CBDCA combination therapy for advanced non-small cell lung cancer which is previously treated with platinum-based chemotherapy
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000011669
- Lead Sponsor
- Dokkyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Not provided
1) Symptomatic brain metastasis 2) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy 3) With active double cancer or multicentric cancer 4) Treated with radiotherapy within the past four weeks. 5) With a history of the treatment with taxane. 6) With clinically important complications. 7) Interstitial pneumonia or pulmonary fibrosis becomes the clinical problem 8) With pleural effusion or pericardial effusion accumulates which need drainage 9) With the history of hypersensivity for nab-paclitaxel, CBDCA 10) Main organs had a serious medical risk factor, and the physicians judged treatment not to be safe. 11) Physician concludes that the patient's participation in this trial is inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method